drugset / Trial / NCT05830097
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of CBP-1019, a bi-specific ligand conjugated drugs in patients with advanced solid tumors.
Timeline
- Start
- 2023-03-14
- Primary completion
- 2025-06-30
- Completion
- 2025-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CBP-1019 | Other / unclassified | — | Intravenous |